Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety,
tolerability and pharmacokinetics of TWP-101 in patients with advanced melanoma and
urothelial carcinoma. This study consists of two parts (Part A and Part B). Part A was a dose
escalation study, and Part B was a dose expansion study.